Zydus, PIeris To Collaborate On Anticalin-Protein Molecule Drugs
This article was originally published in PharmAsia News
Executive Summary
Zydus Cadila and Germany's Pieris have signed an agreement to co-develop and market drugs based on the anticalin protein molecule.